Gene Therapy Global Access Map
Explore where FDA/EMA/MHRA-approved gene therapies are available worldwide, compare pricing by country, and understand global inequality in access to genetic medicine.
8
Approved Gene Therapies
10
Countries / Regions
$594K – $3.5M
Price Range
~4,000+
Patients Treated (est.)
1Select a Therapy
Choose a specific gene therapy to see where it is available, or browse all therapies by region below.
2Access by Region
Click a region to see which therapies are approved there.
3All Approved Gene Therapies
Overview of every approved gene therapy with global availability.
The Gene Therapy Access Gap
Life-saving gene therapies are overwhelmingly concentrated in wealthy nations, leaving the vast majority of patients worldwide without access.
Sickle Cell Paradox
Sickle cell disease has its highest burden in sub-Saharan Africa, where approximately 75% of global cases occur. Yet Casgevy costs $2.2M and is only available in the US, UK, EU, and a handful of Middle Eastern countries. Zero approved gene therapies are available in Africa.
Price vs. Income
The most expensive gene therapy (Hemgenix at $3.5M) costs more than 40x the median US household income. In low-income countries, it would equal thousands of years of average earnings. No low- or middle-income country has a domestically approved gene therapy.
Manufacturing Bottleneck
Gene therapies require specialized manufacturing (GMP viral vector production) available at only a handful of facilities worldwide. Strimvelis is only available at one hospital in Milan. This limits scalability and drives up costs globally.
What is being done?
- •WHO Essential Medicines: The WHO is evaluating gene therapies for potential inclusion on the Essential Medicines List, which could drive negotiated pricing for low-income nations.
- •Outcome-based pricing: Some manufacturers (Novartis, Spark) offer outcome-based payment models — full payment only if the therapy works. This shifts financial risk from healthcare systems to manufacturers.
- •Managed access programs: Companies like Novartis previously ran a “free gene therapy lottery” for Zolgensma in countries without approval. Many manufacturers offer compassionate use programs.
- •In-vivo approaches: Next-generation in-vivo gene editing (delivered via LNP injection) could dramatically reduce manufacturing complexity and cost compared to current ex-vivo approaches requiring per-patient cell harvesting.
Disclaimer: Pricing data is approximate and based on publicly available list prices in USD. Actual costs may vary significantly based on insurance coverage, negotiated rates, government subsidies, and patient assistance programs. Availability changes frequently as new approvals are granted and market dynamics shift. Contact therapy manufacturers or your healthcare provider for current access information. Data last reviewed March 2026.